Literature DB >> 20573813

Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.

Gregory Q Del Prete1, George J Leslie, Beth Haggarty, Andrea P O Jordan, Josephine Romano, James A Hoxie.   

Abstract

During the course of infection, transmitted HIV-1 isolates that initially use CCR5 can acquire the ability to use CXCR4, which is associated with an accelerated progression to AIDS. Although this coreceptor switch is often associated with mutations in the stem of the viral envelope (Env) V3 loop, domains outside V3 can also play a role, and the underlying mechanisms and structural basis for how X4 tropism is acquired remain unknown. In this study we used a V3 truncated R5-tropic Env as a starting point to derive two X4-tropic Envs, termed DeltaV3-X4A.c5 and DeltaV3-X4B.c7, which took distinct molecular pathways for this change. The DeltaV3-X4A.c5 Env clone acquired a 7-amino-acid insertion in V3 that included three positively charged residues, reestablishing an interaction with the CXCR4 extracellular loops (ECLs) and rendering it highly susceptible to the CXCR4 antagonist AMD3100. In contrast, the DeltaV3-X4B.c7 Env maintained the V3 truncation but acquired mutations outside V3 that were critical for X4 tropism. In contrast to DeltaV3-X4A.c5, DeltaV3-X4B.c7 showed increased dependence on the CXCR4 N terminus (NT) and was completely resistant to AMD3100. These results indicate that HIV-1 X4 coreceptor switching can involve (i) V3 loop mutations that establish interactions with the CXCR4 ECLs, and/or (ii) mutations outside V3 that enhance interactions with the CXCR4 NT. The cooperative contributions of CXCR4 NT and ECL interactions with gp120 in acquiring X4 tropism likely impart flexibility on pathways for viral evolution and suggest novel approaches to isolate these interactions for drug discovery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573813      PMCID: PMC2919036          DOI: 10.1128/JVI.00333-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  95 in total

1.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop.

Authors:  T M Ross; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

3.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

4.  Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor.

Authors:  L O Gerlach; R T Skerlj; G J Bridger; T W Schwartz
Journal:  J Biol Chem       Date:  2001-01-11       Impact factor: 5.157

5.  Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion.

Authors:  L Picard; G Simmons; C A Power; A Meyer; R A Weiss; P R Clapham
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Authors:  Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

7.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

8.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

9.  Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.

Authors:  A Koito; G Harrowe; J A Levy; C Cheng-Mayer
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection.

Authors:  A Karlsson; K Parsmyr; E Sandström; E M Fenyö; J Albert
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

View more
  8 in total

1.  Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.

Authors:  A Gonzalez-Serna; R A McGovern; P R Harrigan; F Vidal; A F Y Poon; S Ferrando-Martinez; M A Abad; M Genebat; M Leal; E Ruiz-Mateos
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Interaction of the HIV-1 gp120 viral protein V3 loop with bacterial lipopolysaccharide: a pattern recognition inhibition.

Authors:  Andreja Majerle; Primoz Pristovsek; Mateja Mancek-Keber; Roman Jerala
Journal:  J Biol Chem       Date:  2011-06-02       Impact factor: 5.157

3.  Longitudinal Analysis of Cerebrospinal Fluid and Plasma HIV-1 Envelope Sequences Isolated From a Single Donor with HIV Asymptomatic Neurocognitive Impairment.

Authors:  Fabián Vázquez-Santiago; Yashira García; Ivelisse Rivera-Román; Richard J Noel; Valerie Wojna; Loyda M Meléndez; Vanessa Rivera-Amill
Journal:  J Virol Antivir Res       Date:  2015

4.  Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus.

Authors:  Adrienne E Swanstrom; Beth Haggarty; Andrea P O Jordan; Josephine Romano; George J Leslie; Pyone P Aye; Preston A Marx; Andrew A Lackner; Gregory Q Del Prete; James E Robinson; Michael R Betts; David C Montefiori; Celia C LaBranche; James A Hoxie
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

5.  Study of compartmentalization in the visna clinical form of small ruminant lentivirus infection in sheep.

Authors:  Hugo Ramírez; Ramsés Reina; Luigi Bertolotti; Amaia Cenoz; Mirna-Margarita Hernández; Beatriz San Román; Idoia Glaria; Ximena de Andrés; Helena Crespo; Paula Jáuregui; Julio Benavides; Laura Polledo; Valentín Pérez; Juan F García-Marín; Sergio Rosati; Beatriz Amorena; Damián de Andrés
Journal:  BMC Vet Res       Date:  2012-01-26       Impact factor: 2.741

6.  Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus.

Authors:  George J Leslie; Jianbin Wang; Max W Richardson; Beth S Haggarty; Kevin L Hua; Jennifer Duong; Anthony J Secreto; Andrea P O Jordon; Josephine Romano; Kritika E Kumar; Joshua J DeClercq; Philip D Gregory; Carl H June; Michael J Root; James L Riley; Michael C Holmes; James A Hoxie
Journal:  PLoS Pathog       Date:  2016-11-17       Impact factor: 6.823

7.  A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection.

Authors:  Zachary A Silver; Gordon M Dickinson; Michael S Seaman; Ronald C Desrosiers
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

8.  Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc.

Authors:  Borislav Savkovic; Geoff Symonds; John M Murray
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.